A new era in the treatment of chronic lymphocytic leukemia and a part of lymphoma: reports in the 55th ASH annual meeting
10.3760/cma.j.issn.1009-9921.2014.01.001
- VernacularTitle:慢性淋巴细胞白血病及部分淋巴瘤治疗迎来一个崭新时代:第55届美国血液学会年会报道
- Author:
Jun MA
;
Lin QIU
- Publication Type:Journal Article
- Keywords:
Leukemia,lymphocytic,chronic;
Lymphoma;
Targeting therapy;
ASH annual meeting
- From:
Journal of Leukemia & Lymphoma
2014;23(1):1-2
- CountryChina
- Language:Chinese
-
Abstract:
In this year,ASH annual meeting reported several new targeting therapeutic drugs for chronic lymphocytic leukemia (CLL) and a part of lymphoma.Those drugs focus on some key targets in the signal transductional pathway of B cells.Although these targeting drugs individually did not improve the complete remission rate of CLL,but several clinical trial results showed that the combination therapy of those drugs with other drugs significantly improved the efficacy of CLL,and prolonged the progression-free survival of CLL patients.Therefore,experts believe that combination therapy and sequential therapy will start a new era in the treatment of CLL.This paper will share only the latest advances in the treatment of CLL and parts of lymphoma with domestic readers.
